MediWound to Report First Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time YAVNE,…
News
Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022…
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE…
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, May 12, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical…
Reflect Scientific Inc Reports First Quarter 2023 Results
OREM, Utah, May 12, 2023 (GLOBE NEWSWIRE) — Reflect Scientific, Inc. (OTCQB: RSCF), a provider…
IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels…
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement Priced At-the-Market
MONTREAL, May 12, 2023 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company…
Spectral Medical Announces First Quarter Results and Provides Corporate Update
New Trial Sites Enroll 60% of New Patient Enrollments Since the Beginning of April Tigris…
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results
— New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left…
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
SCYNEXIS is receiving an upfront payment of $90 million with future performance-based milestone payments of…
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a…
Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned…
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets…
Psychedelic Science 2023 Announces Sessions and Select Featured Speakers for the Therapy and Practitioners Tracks for June Conference
Dr. Rachel Yehuda to Lead Discussions on Therapeutic Application of Psychedelics Additional Featured Speakers Include…
LifeMD, Inc. Reports First Quarter 2023 Results; Record Revenues and Adjusted EBITDA
Record first quarter 2023 consolidated revenue of $33.1 million, up 14% from the same year-ago…
Humacyte First Quarter 2023 Financial Results and Business Update
– Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma…
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across…
Bio-Path Holdings Reports First Quarter 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May 12, 2023 (GLOBE…
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO
CTA authorization provides approval for the Company to expand its planned CHORD™ Phase 1/2 clinical…
Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event
AUSTIN, Texas, May 12, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a…